Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia

Alejandro Roman-Gonzalez,Carlos Andrés Naranjo,Walter D. Cardona-Maya,1,3 Dionis Vallejo,Francisco Garcia,5 Cesar Franco,Leonor Alvarez,Luis Ignacio Tobón,Marta Ibeth López,Carolina Rua,Gabriel Bedoya,Ángela Cadavid,1,3 and José Domingo Torres1

1Grupo de Investigación en Trombosis, Universidad de Antioquia-UdeA, Colombia
2Grupo GENMOL, Universidad de Antioquia-UdeA, Colombia
3Grupo Reproducción, Universidad de Antioquia-UdeA, Colombia
4Departamento de Neurología, Universidad de Antioquia-UdeA, Colombia
5Departamento de Neurología, Hospital Universitario San Vicente Fundación, Colombia
6Instituto Neurológico de Antioquia, Colombia

Correspondence should be addressed to José Domingo Torres; domingo.torres@udea.edu.co

Received 9 March 2021; Accepted 11 May 2021; Published 22 May 2021

Academic Editor: Taskin Duman

Copyright © 2021 Alejandro Roman-Gonzalez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the aspirin resistance prevalence in patients with previous ischemic cerebrovascular disease undergoing aspirin therapy for secondary prevention. Materials and Methods. Three hundred fifty patients presenting ischemic strokes and 100 healthy controls under aspirin treatment were evaluated using the optic platelet aggregation test. Results. Aspirin resistance was found in 7.4% of the patients with ischemic stroke and 4% of controls. Aspirin resistance was associated with stroke recurrence in univariate analysis (p = 0.004). Aspirin resistance was not associated with smoking, diabetes, or hypercholesterolemia. Conclusion. Aspirin resistance is present in Colombian patients with ischemic stroke as well as in healthy controls.

1. Introduction

Cerebrovascular disease is the second leading cause of death worldwide, the leading cause of death in high-income countries, and the fifth cause of death in low-income countries. Its prevalence is projected to increase in all geographical areas by 2030. Stroke is also a common cause of disability-adjusted life years and imposes a tremendous economic and social burden [1, 2].

A significant proportion of the global stroke burden is due to stroke occurrence in patients with previous strokes or transient ischemic attacks. Although the recurrence for stroke is common and the risk factors for it have been identified, there is substantial under treatment and a lack of control of these factors [3].

A mainstay for secondary prevention of stroke is tight control of risk factors and aspirin therapy [3–5]. This drug decreases the recurrence of stroke by 22% [6]. However, previous data indicate that some patients present aspirin resistance (AR) determined by the platelet function test, mainly by optic platelet aggregation [7–13]. The exact cause of this phenomenon is unclear, and genetic as well as clinical factors have been associated with AR [14]. A critical point in the AR discussion explores if AR is related to adverse outcomes compared to patients without AR. In this sense, two meta-analyses and systematic reviews including 20 studies support that AR is associated with recurrent cardiovascular events, acute coronary syndrome, and death [15, 16].

In stroke patients, the prevalence of AR is variable [17, 18]. No studies have evaluated the presence of AR in populations.
with a stroke from Latin American countries [19], and there is no clear evidence of the associated clinical conditions or the best treatment strategy for resistant patients.

This study is aimed at evaluating the prevalence of AR in patients with previous ischemic cerebrovascular disease undergoing aspirin therapy for secondary prevention. The patients were compared to healthy controls of similar age; AR was evaluated using optical platelet aggregation.

2. Materials and Methods

2.1. Study Population. Three hundred fifty patients with previous history of ischemic stroke were included. All patients had previously suffered one or more ischemic strokes diagnosed by a neurologist (based on clinical findings and confirmatory imaging) and were on continuous uncoated aspirin therapy for at least seven days before the sample was taken. Exclusion criteria included ingestion of nonsteroidal anti-inflammatory agents (except low dose aspirin), warfarin, ticlopidine or clopidogrel, previous surgery in the past month, paraproteinemia, thrombocytopenia, anemia, and personal or familial history suggestive of bleeding disorders. Hypertension was defined as blood pressure higher than 140/90 mmHg or treatment with any antihypertensive drug. Diabetes mellitus and hypercholesterolemia were diagnosed based on the American Diabetes Association criteria [20] and the Adult Panel Treatment III for high cholesterol levels [21], respectively. Recurrence of ischemic stroke was defined as more than one cerebrovascular event. Adherence to aspirin was evaluated by questionnaire. Optical platelet aggregation was measured. Informed consent explaining this study’s objectives and ethical approval from the Research Ethics Committee of the University of Antioquia and the Hospital San Vicente Fundación were obtained.

2.2. Control Population. One hundred healthy individuals older than 18 years were included. None had a previous history of a cardio cerebrovascular disease or bleeding disorder. All controls received uncoated aspirin (100 mg/day) for one week, and an optical platelet aggregation test was performed before and after aspirin intake.

2.3. Optical Platelet Aggregation. The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, Helena Laboratories, Texas, USA), using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm³. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer’s instructions.

AR was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate [22].

2.4. Statistical Analysis. The statistical analysis was performed using a proportion comparison and the Mann-Whitney Test for compared qualitative variables or quantitative variables, respectively. Differences were considered significant when 𝑝 ≤ 0.05. All statistical tests were performed using GraphPad Software, version 8.0 (La Jolla, CA, USA).

3. Results

A total of 450 individuals compromised the total population studied; 350 patients who had had a previous stroke were in the patient group, and 100 subjects were included in the control group. The patient group had a mean age of 65.6 years and was equally distributed in terms of gender; the control group was predominantly female (74%) with a mean age of 60.8 years. The control group had no history of cardiocerebrovascular events and was considered healthy given the low frequency or absence of cardiovascular risk factors. The demographic and clinical characteristics of both groups are shown in Table 1.

AR was found in 26 patients (7.4%) and 4 controls (4%) (𝑝 = 0.225). All of the subjects with AR defined as optic platelet aggregation ≥ 20% with arachidonic acid and >70% with adenosine diphosphate had optic platelet aggregation ≥70% with both collagen and epinephrine except for three patients. All patients with aspirin resistance had higher platelet aggregation with all the stimuli tested (𝑝 < 0.0001, data not shown) compared with aspirin sensitive patients.

AR was not associated with clinical risk factors of stroke. However, 46.2% of AR patients had a history of a prior stroke recurrence, with 21.3% of patients who responded to aspirin (𝑝 = 0.004) (Table 2).

Although no differences were found in terms of risk factors in recurrent stroke patients, a high prevalence of risk factors in this population, mainly hypertension, was found.

4. Discussion

The most frequently used antiplatelet therapy is aspirin, which is associated with risk factor control as the first option for secondary prophylaxis of cerebrovascular disease. However, some patients develop recurrent strokes, and AR has been postulated as an essential contributor to this therapeutic failure. Several studies support this phenomenon in patients with cardiovascular disease [23–26] and stroke [8, 10, 27–30]. The prevalence of AR is variable in these studies, but the different evaluation methods and definition criteria for AR and differences in the population studied limit the possibility of grouped analysis and reliable conclusions. The prevalence of AR in our study (7.4%) by optical platelet aggregometry is comparable to the AR published in other populations (5% to 24%) [31–33].

We found that patients with AR had more history of previous ischemic strokes than patients without AR (46.2% vs. 21.3%, 𝑝 = 0.004). Therefore, a link between AR and stroke recurrence can be suggested. The retrospective evaluation of recurrent stroke in this study limits our conclusions of stroke recurrence and AR. However, supportive evidence from other studies also suggests that AR is associated with severe vascular events’ recurrence. A prospective trial by Gum et al. [22] found that AR evaluated by optic platelet aggregation increased the risk of death, myocardial infarction, and stroke. Systematic reviews and meta-analysis confirm the
higher risk of cardiovascular events in patients with AR [15, 16]. Specifically, in stroke, other researchers have found similar findings [12, 15, 16].

AR was found in healthy controls (4%). The meaning of this finding is essential given the current recommendations of the U.S Preventive Task Force for aspirin use, as primary prophylaxis in persons at risk of myocardial infarction or stroke, for the prevention of cardiovascular disease [34], raising the question of whether AR has any role in the lack of effect of aspirin for primary prevention, or if the AR test should be performed before starting aspirin therapy.

Another finding of our study was the higher frequency of AR in patients than controls, although this was not statistically significant (7.6% vs. 4% \( p = 0.225 \)). Berrouschot et al. have suggested that some patients can develop secondary AR after continued use of this drug. Other researchers have found that AR is associated with risk factors with confirmed prothrombotic risk, such as smoking, hypercholesterolemia, and diabetes [35–37]. In the present study, an association between AR and age, gender, and cardiovascular risk factors was not observed, and these results are congruent with other studies [8, 38].

The underlying causes of aspirin resistance and therapeutic failure are not well understood, although several mechanisms may be involved, such as lack of patient adherence, underdosing, reduced absorption and increased metabolism of aspirin, biosynthesis of TXA2 from pathways not inhibited by aspirin, alternative ways involved in platelet activation not blocked by aspirin, cigarette smoking, and hypercholesterolemia.

The presence of AR in healthy controls suggests a genetic basis for this phenomenon. Several studies have examined the association of AR with a polymorphism in the COX enzyme and a number of receptors present on the surface of platelets [15, 39–41].

5. Conclusions

We conclude that AR is present in stroke patients from a cohort of patients in Colombia, and the frequency of detection are similar to that reported in other countries. AR is possibly associated with stroke recurrence and is a contributing factor in aspirin’s therapeutic failure in stroke. However, a multifactorial scenario cannot be ruled out. The benefits of AR determination in ischemic stroke previous to and at the beginning of therapy are unknown but could be recommended given the association between AR and recurrent events in our study and the findings from other studies [15, 16]. More prospective studies with longer follow-ups are needed to determine the best treatment options for these patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

No competing financial interests exist. The authors report no conflicts of interest.

Acknowledgments

We gratefully thank the staff of the Hospital Universitario San Vicente de Paul, Instituto Neurológico de Antioquia, and the long-term care facility “Los recuerdos” for their help with the recruitment of patients and control subjects. This work was supported by grant (1115-04-18130) from Colciencias and Universidad de Antioquia.

References

[1] L. Schlemm, “Disability adjusted life years due to ischaemic stroke preventable by real-time stroke detection—a cost-utility analysis of hypothetical stroke detection devices,” *Frontiers in Neurology*, vol. 9, p. 814, 2018.

[2] S. Virani, A. Alonso, E. J. Benjamin et al., "Heart disease and stroke statistics-2020 update: a report from the American
Heart Association," *Circulation*, vol. 141, no. 9, pp. e139–e596, 2020.

[3] F. M. Yatsu, T. Yamaguchi, and B. Norrving, "International aspects of global stroke burden," *International Journal of Stroke*, vol. 1, no. 4, pp. 222–223, 2006.

[4] R. Bonita, S. Mendis, T. Truelson, J. Bogousslavsky, J. Toole, and F. Yatsu, "The global stroke initiative," *Lancet Neurology*, vol. 3, no. 7, pp. 391–393, 2004.

[5] J. M. Rothlisberger and B. Ovbiagele, "Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost–effectiveness," *Journal of comparative effectiveness research*, vol. 4, no. 4, pp. 377–384, 2015.

[6] Antithrombotic Trialists’ Collaboration, "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients," *BMJ*, vol. 324, no. 7330, pp. 141–186, 2002.

[7] D. Bennett, B. Yan, L. MacGregor, D. Eccleston, and S. M. Davis, "A pilot study of resistance to aspirin in stroke patients," *Journal of Clinical Neuroscience*, vol. 15, no. 11, pp. 1204–1209, 2008.

[8] J. Berrouschot, B. Schbelticke, G. Twickel et al., "Aspirin resistance in secondary stroke prevention," *Acta Neurologica Scandinavica*, vol. 113, no. 1, pp. 31–35, 2006.

[9] N. A. Englyst, G. Horsfield, J. Kwan, and C. D. Byrne, "Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity," *Journal of Cerebral Blood Flow and Metabolism*, vol. 28, no. 6, pp. 1196–1203, 2008.

[10] C. M. Helgason, K. M. Bolin, J. A. Hoff et al., "Development of aspirin resistance in persons with previous ischemic stroke," *Stroke*, vol. 25, no. 12, pp. 2331–2336, 1994.

[11] L. Macchi, E. Petit, A. Brizard, R. Gil, and J. P. Neau, "Aspirin resistance in vitro and hypertension in stroke patients," *Journal of Thrombosis and Haemostasis*, vol. 2, no. 11, pp. 2051–2053, 2004.

[12] K. Grundmann, K. Jaschonek, B. Kleine, J. Dichgans, and H. Topka, "Aspirin non-responder status in patients with recurrent cerebral ischemic attacks," *Journal of Neurology*, vol. 250, no. 1, pp. 63–66, 2003.

[13] S. Patel, V. Arya, A. Saraf, M. Bhargava, and C. S. Agrawal, "Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: a pilot study," *Annals of Indian Academy of Neurology*, vol. 22, no. 2, pp. 147–152, 2019.

[14] S. Sanderson, J. Emery, T. Baglin, and A. L. Kinmonth, "Narrative review: aspirin resistance and its clinical implications," *Annals of Internal Medicine*, vol. 142, no. 5, pp. 370–380, 2005.

[15] J. D. Snoep, M. C. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman, "Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis," *Archives of Internal Medicine*, vol. 167, no. 15, pp. 1593–1599, 2007.

[16] G. Krasopoulos, S. J. Brister, W. S. Beattie, and M. R. Buchan, "Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis," *BMJ*, vol. 336, no. 7637, pp. 195–198, 2008.

[17] L. K. Sztriha, K. Sas, and L. Vecsei, "Aspirin resistance in stroke: 2004," *Journal of the Neurological Sciences*, vol. 229–230, pp. 163–169, 2005.

[18] D. M. Greer, "Aspirin and antiplatelet agent resistance," *CNS Drugs*, vol. 24, no. 12, pp. 1027–1040, 2010.

[19] S. W. Al-Jabi, "Global trends in aspirin resistance-related research from 1990 to 2015: a bibliometric analysis," *Basic & Clinical Pharmacology & Toxicology*, vol. 121, no. 6, pp. 512–519, 2017.

[20] American Diabetes Association, "Diagnosis and classification of diabetes mellitus," *Diabetes Care*, vol. 32, Supplement 1, pp. S62–S67, 2009.

[21] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)," *JAMA*, vol. 285, no. 19, pp. 2486–2497, 2001.

[22] P. A. Gum, K. Kottke-Marchant, P. A. Welsh, J. White, and E. J. Topol, "A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease," *Journal of the American College of Cardiology*, vol. 41, no. 6, pp. 961–965, 2003.

[23] P. A. Gum, K. Kottke-Marchant, E. D. Poggio et al., "Profile and prevalence of aspirin resistance in patients with cardiovascular disease," *The American Journal of Cardiology*, vol. 88, no. 3, pp. 230–235, 2001.

[24] A. J. Peters, M. Borries, F. Gradaus, T. W. Jax, F. C. Schoebel, and B. E. Stauer, "In vitro bleeding test with PFA-100™: aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease," *Journal of Thrombosis and Thrombolysis*, vol. 12, no. 3, pp. 263–272, 2001.

[25] K. Andersen, M. Hurlen, H. Arnesen, and I. Selje, "Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease," *Thrombos Research*, vol. 108, no. 1, pp. 37–42, 2002.

[26] N. Zimmermann, P. Kienle, A. A. Weber et al., "Aspirin resistance after coronary artery bypass grafting," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 121, no. 5, pp. 982–984, 2001.

[27] K. H. Grotemeyer, "Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subgroup of treated patients," *Thrombosis Research*, vol. 63, no. 6, pp. 587–593, 1991.

[28] K. H. Grotemeyer, H. W. Scharafinski, and I. W. Husstedt, "Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients," *Thrombosis Research*, vol. 71, no. 5, pp. 397–403, 1993.

[29] M. J. Alberts, D. L. Bergman, E. Molner, B. D. Jovonovic, I. Ushiwata, and J. Teruya, "Antiplatelet effect of aspirin in patients with cerebrovascular disease," *Stroke*, vol. 35, no. 1, pp. 175–178, 2004.

[30] P. Harrison, H. Segal, K. Blasbery, C. Furtado, L. Silver, and P. M. Rothwell, "Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry," *Stroke*, vol. 36, no. 5, pp. 1001–1005, 2005.

[31] C. Patrono, "Aspirin resistance: definition, mechanisms and clinical read-outs," *Journal of Thrombosis and Haemostasis*, vol. 1, no. 8, pp. 1710–1713, 2003.

[32] G. J. Hankey and J. W. Eikelboom, "Aspirin resistance," *Lancet*, vol. 367, no. 9510, pp. 606–617, 2006.

[33] D. L. Bhatt, "Aspirin resistance: more than just a laboratory curiosity," *Journal of the American College of Cardiology*, vol. 43, no. 6, pp. 1127–1129, 2004.
[34] N. Calonge, D. B. Petitti, T. G. DeWitt et al., “Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement,” *Annals of internal medicine*, vol. 150, no. 6, pp. 396–404, 2009.

[35] N. Gastón Dussaillant, M. Mario Zapata, B. Patricia Fardella, L. Guillermo Conte, and V. Marianela Cuneo, “Frecuencia y características de la resistencia a aspirina en pacientes cardiovasculares chilenos,” *Revista Médica de Chile*, vol. 133, no. 4, pp. 409–417, 2005.

[36] A. Szczeklik, A. Undas, M. Sanak, M. Frołow, and W. Węgrzyn, “Relationship between bleeding time, aspirin and the PLA1/A2 polymorphism of platelet glycoprotein IIIa,” *British Journal of Haematology*, vol. 110, no. 4, pp. 965–967, 2000.

[37] A. Szczeklik, J. Musial, A. Undas et al., “Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 16, no. 8, pp. 948–954, 1996.

[38] J. I. Seok, I. S. Joo, J. H. Yoon et al., “Can aspirin resistance be clinically predicted in stroke patients?,” *Clinical Neurology and Neurosurgery*, vol. 110, no. 2, pp. 110–116, 2008.

[39] T. Goodman, P. Sharma, and A. Ferro, “The genetics of aspirin resistance,” *International Journal of Clinical Practice*, vol. 61, no. 5, pp. 826–834, 2007.

[40] L. Macchi, L. Christiaens, S. Brabant et al., “Resistance in vitro to low-dose aspirin is associated with platelet PLA1(GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms,” *Journal of the American College of Cardiology*, vol. 42, no. 6, pp. 1115–1119, 2003.

[41] A. O. Maree, R. J. Curtin, A. Chubb et al., “Cyclooxygenase-1 haplotype modulates platelet response to aspirin,” *Journal of Thrombosis and Haemostasis*, vol. 3, no. 10, pp. 2340–2345, 2005.